Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Maddocks

Showing results (51-60 of 215) with videos related to

Pageof 22
Sort By:
Blood|June 28, 2015
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 studySamantha M Jaglowski, Jeffrey A Jones, Veena Nagar, et al.
Blood Advances|January 4, 2018
Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinibCecelia R Miller, Amy S Ruppert, Nyla A Heerema, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 30, 2022
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World ExperienceMuhammad Saad Hamid, Sarah C Rutherford, Hyejeong Jang, et al.
Cancer|July 28, 2017
C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapyNarendranath Epperla, Kami J Maddocks, Mohammed Salhab, et al.
American Journal of Hematology|January 2, 2023
Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective studyBrian T Hess, Anshu Giri, Yeonhee Park, et al.
Blood Advances|August 22, 2025
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN StudyNirav N Shah, Pier Luigi Zinzani, Michael L Wang, et al.
JCI Insight|February 7, 2023
Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell-targeted therapyJoseph H Azar, John P Evans, Madison H Sikorski, et al.
American Journal of Hematology|July 29, 2021
Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab eraReem Karmali, Jeffrey M Switchenko, Subir Goyal, et al.
Blood Advances|January 17, 2020
Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogeneticsPallawi Torka, Shalin K Kothari, Suchitra Sundaram, et al.
Bone Marrow Transplantation|August 20, 2021
ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphomaPashna N Munshi, Mehdi Hamadani, Ambuj Kumar, et al.
Pageof 22

Showing results (51-60 of 215) with videos related to

Sort By:
Pageof 22
Blood|June 28, 2015
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 studySamantha M Jaglowski, Jeffrey A Jones, Veena Nagar, et al.
Blood Advances|January 4, 2018
Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinibCecelia R Miller, Amy S Ruppert, Nyla A Heerema, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 30, 2022
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World ExperienceMuhammad Saad Hamid, Sarah C Rutherford, Hyejeong Jang, et al.
Cancer|July 28, 2017
C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapyNarendranath Epperla, Kami J Maddocks, Mohammed Salhab, et al.
American Journal of Hematology|January 2, 2023
Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective studyBrian T Hess, Anshu Giri, Yeonhee Park, et al.
Blood Advances|August 22, 2025
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN StudyNirav N Shah, Pier Luigi Zinzani, Michael L Wang, et al.
JCI Insight|February 7, 2023
Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell-targeted therapyJoseph H Azar, John P Evans, Madison H Sikorski, et al.
American Journal of Hematology|July 29, 2021
Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab eraReem Karmali, Jeffrey M Switchenko, Subir Goyal, et al.
Blood Advances|January 17, 2020
Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogeneticsPallawi Torka, Shalin K Kothari, Suchitra Sundaram, et al.
Bone Marrow Transplantation|August 20, 2021
ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphomaPashna N Munshi, Mehdi Hamadani, Ambuj Kumar, et al.
Pageof 22